Revised forecast
Fiscal year ending March 2026 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
In August 2025, Sumitomo Pharma acquired substantially all assets and other items, including the patent rights, related to three key products in the United States and other products, and recorded sales of those products, resulting in higher net sales. The increase in net sales led to higher operating profit, while ordinary profit increased due to the recognition of dividends received from SMPS and other factors. In addition, net income exceeded the previous fiscal year's result due to the recognition of a gain on the sale of shares in an affiliate arising from the transfer of part of the Asian business and other factors.
| Item | Details |
|---|---|
| Net Sales | 113,118 |
| Operating profit | 7,756 |
| Ordinary income | 50,912 |
| Profit attributable to owners of the parent | 8,794 |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Previous-period results | Net sales: ¥136,412 million; operating profit: ¥11,603 million; ordinary profit: ¥12,028 million; net income: ¥106,187 million |
| Reason for the revision | In August 2025, Sumitomo Pharma acquired substantially all assets and other items, including the patent rights, related to three key products in the United States and other products, and recorded sales of those products, resulting in higher net sales. The increase in net sales led to higher operating profit, while ordinary profit increased due to the recognition of dividends received from SMPS and other factors. In addition, net income exceeded the previous fiscal year's result due to the recognition of a gain on the sale of shares in an affiliate arising from the transfer of part of the Asian business and other factors. |
| Consolidated / non-consolidated | Non-consolidated |
Items this document does not state (4)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In August 2025, Sumitomo Pharma acquired the assets of three key products in the United States and other assets, and recorded sales of those products, resulting in higher net sales and operating profit. In addition, dividends received from SMPS and a gain on the sale of shares in an affiliate arising from the transfer of part of the Asian business contributed to increases in ordinary profit and net income.